The total market size of non-alcoholic steatohepatitis (NASH) is anticipated to upsurge during the forecast period due to the expected entry of emerging therapies that include MGL-3196 (Resmetirom), Lanifibranor/ IVA337, Efruxifermin, and others. LAS VEGAS, Jan. 17, 2024 /PRNewswire/ –…